MILNACIPRAN HYDROCHLORIDE

Post-LOE

milnacipran hydrochloride

R-Pharm US

ANDAORALTABLET

Approved

Jan 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MILNACIPRAN HYDROCHLORIDE (milnacipran hydrochloride) by R-Pharm US is unknown. Approved for fibromyalgia (). First approved in 2016.

Drug data last refreshed 1w ago

Mechanism of Action

unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other…

Indications (1)

fibromyalgia ()

Worked on MILNACIPRAN HYDROCHLORIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.